Vamorolone

(Agamree®)

Vamorolone

Drug updated on 11/17/2023

Dosage FormSuspension (oral: 40 mg/mL)
Drug ClassCorticosteroid
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.

Product Monograph / Prescribing Information

Document TitleYearSource
Agamree (vamorolone) Prescribing Information. 2023Santhera Pharmaceuticals (USA), Inc., Burlington MA

Systematic Reviews / Meta-Analyses